secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2026-05-18T21:00:15+00:00
Accession:  0001193125-26-229089
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics enters new ATM with Jefferies; says not PFIC for 2025
--------------------------------------------------------------------------

- Entered at-the-market equity offering agreement with Jefferies LLC; prior 2021 ATM agreement terminated.
- Jefferies receives 3.0% commission on gross proceeds; no minimum obligation to sell ADSs.
- After further tax analysis, company believes it was not a PFIC for FY 2025 (previously disclosed potential PFIC status).
- Added risk factor noting PFIC classification is fact-intensive and could change; no assurance from IRS.
- Legal opinion from Cooley (UK) LLP on ADS validity filed as exhibit 5.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526229089/0001193125-26-229089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526229089/sln-20260518.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-229089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer